The extended interaction of aldoses with proteins or lipids results in nonenzymatic glycation and oxidation, ultimately forming AGEs, the presence of which in the plasma and vessel wall is associated with diabetic vascular complications. We show here that AGE albumin in the intravascular space interacts with the vessel wall via binding to an integral membrane protein, receptor for AGE (RAGE), a member of the immunoglobulin superfamily, resulting in clearance from the plasma and induction of interleukin 6 mRNA. Intravenously infused 2SI-AGE albumin showed a rapid phase of plasma clearance with deposition in several organs. Rapid removal of 125I-AGE albumin from the plasma was prevented by administration ofa soluble, truncated form ofRAGE, which blocked binding of 12I-labeled AGE albumin to cultured endothelial cells and mononuclear phagocytes, as well as by pretreatment with anti-RAGE IgG. Ultrastructural studies with AGE albumin-colloidal gold conjugates perfused in situ showed that in murine coronary vasculature this probe was taken up by endothelial plasmalemmal vesicles followed by transport either to the abluminal surface or by accumulation in intracellular vesicular structures reminint ofendosomes and lysosomes. Consequences of AGE-RAGE interaction included induction of interleukin 6 mRNA expression in mice. These data indicate that RAGE mediates the interaction ofAGEs with the vessel wall, both for removal ofthese glycated proteins from the plasma and for changes in gene expression.
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When proteins or lipids are exposed to aldoses, they undergo nonenzymatic glycation and oxidation (1) (2) (3) (4) (5) (6) (7) (8) , ultimately forming AGEs, whose formation occurs during normal aging and is accelerated in diabetics (1) (2) (3) (4) (5) (6) (7) . The presence of AGEs in the plasma and vessel wall has been linked to the pathogenesis of diabetic complications, stimulating investigations to determine mechanisms through which AGEs exert their pathologic effects.
An important mechanism through which AGEs interact with cells is through specific receptors (9) (10) (11) (12) (13) . We thus evaluated the role of the receptor for AGE (RAGE), which specifically binds AGEs (10) (11) (12) , in mediating the interactions of these glycated molecules with target cells such as endothelial cells (ECs) and mononuclear phagocytes (MPs) (10, 11, 13) . Previous studies have identified the presence of RAGE in bovine cardiac vasculature (13) . We have now identified RAGE in murine coronary vasculature both in vivo and in vitro and employed this model to demonstrate that RAGE has a central role in uptake by the endothelium and in gene expression following AGE infusion.
MATERIALS AND METHODS
Preparation of AGE Albumin, RAGE, and Anti-RAGE Antibody. Mouse and bovine AGE albumin were prepared and characterized as described (2, 10, 11) . Radiolabeling of AGE and native albumin was performed by the lactoperoxidase method (14) ; the tracers had specific radioactivities of -1.5 x 104 cpm/ng (10, 11) . For AGE albumin-gold conjugates, colloidal gold particles (5 nm in diameter) were prepared as described (15, 16) . Bovine RAGE and monospecific rabbit anti-RAGE IgG were prepared and characterized as described (11) . The -35-kDa form of bovine RAGE was termed soluble RAGE (sRAGE; refs. 10 and 12).
Cell Binding Assays. Binding of 1251-AGE albumin to cultured bovine adrenal capillary ECs or human MPs was studied as described (10, 11, 17) .
Infusion/Uptake Studies. 125I-labeled AGE albumin or 1251-labeled native albumin (-3 Mg) was infused via the tail vein of CD1 mice with or without preincubation with a 50-fold molar excess of sRAGE or preinfusion of the animals with either anti-RAGE IgG or nonimmune IgG. To assess tissue deposition, organs were removed and the weight and radioactivity (cpm) were measured (18) . The method of Spady et al. (19) was used to calculate the tissue spaces. To correct for nonspecific tissue trapping of tracer, a tissue space for 125I-albumin was calculated (18) . All preparations of proteins utilized in infusion studies were tested in the Limulus amebocyte assay (Sigma) for lipopolysaccharide content and, where indicated, were chromatographed on Detoxi-Gel columns (Pierce). Inactive heat-treated AGE albumin (boiled for 15 min) was also employed. Effect of AGE Albumin Infusion on Levels of Interleukin 6 (IL-6) Transcripts. Three hours after AGE albumin infusion, mice were sacrificed, livers were excised, total RNA was extracted, and poly(A)+ mRNA was prepared (20, 21) . Random hexanucleotide-primed first-strand cDNA served as the template for polymerase chain reaction (PCR) analysis. Murine IL-6 primers and actin primers were obtained from Clontech. cDNA for murine IL-6 was amplified by PCR for 35 cycles, each consisting of incubations at 94°C for 2 min (first cycle) or 45 sec (remaining 34 cycles), 60°C for 45 sec, and 72°C for 2 min followed by 7 min at 72°C linked to 4°C.
A similar protocol was utilized for the /-actin primers except that 25 cycles were employed. Products were separated by 2% agarose gel electrophoresis and transferred to nylon membrane for Southern hybridization with a 32P-labeled oligonucleotide probe for murine IL-6 (Clontech).
Abbreviations: AGE, advanced glycation end product; RAGE, receptor for AGE; sRAGE, soluble RAGE; EC, endothelial cell; MP, mononuclear phagocyte; IL, interleukin.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 Ultrastructural Studies of Vessel Wall Uptake of AGE Albumin. Via laparotomy, aortae were catheterized, and the vasculature was washed free of blood with phosphatebuffered saline (PBS) containing albumin (3.5 mg/ml) by using the vena cava as the outflow track. AGE albumin conjugated to colloidal gold was introduced at a flow rate of 3 ml/min at 37°C for 4 or 15 min. Unbound ligand was removed by perfusing PBS (3 min; 3 ml/min) and then 2.5% formaldehyde/1.5% glutaraldehyde/2.5 mM CaCl2/0.1 M sodium cacodylate HCl buffer (pH 7.2). Thin sections of myocardium were cut on an OmU Reichert Ultramicrotome, stained with uranyl acetate and lead citrate, and examined with a Philips 400 HM electron microscope.
Identification of Murine RAGE Antigen and mRNA in Cardiac Vasculature and Cultured Murine Coronary ECs. RAGE was detected immunohistochemically on freshly harvested mouse cardiac tissue fixed overnight with 3.5% formalin in PBS and on confluent cultured murine coronary ECs (generously provided by R. Auerbach, University of Wisconsin, Madison) fixed in buffered 3.5% paraformaldehyde. After preparation, immunostaining with anti-RAGE IgG was performed as described (13) . In situ hybridization was performed with digoxigenin-labeled RNA probes (13 (Fig. 1A) . sRAGE did not affect binding of 1251-labeled factor IX to cultured ECs (data not shown).
To determine the role of RAGE in the handling of circulating AGEs, infusion studies were performed with 125I1 labeled AGE or native albumin in mice (Fig. 1B) 125I-labeled AGE albumin showed an initial rapid phase of removal from the blood, with =70% of the material gone by 5 min (Fig. 1B  Left) . The deposition of 125I-AGE albumin in the tissues, studied just after the rapid phase of AGE clearance from the blood, was enhanced relative to that of 125I-albumin, especially in the liver, lung, and kidney (Fig. 1B Right) . When 1251-AGE albumin was preincubated with sRAGE and infused into mice (Fig. 1C) , the rapid phase of tracer clearance was largely blocked; sRAGE had no effect on 1251-albumin plasma levels (Fig. 1C Left) . Animals pretreated with anti-RAGE IgG showed an even more complete blockade of the early clearance phase of infused 1251-AGE albumin. The clearance of 125I-albumin was again unaffected (data not shown). Nonimmune IgG had no effect (Fig. ID Left) . Administration of 1251-AGE albumin with sRAGE or pretreatment with anti-RAGE IgG prior to 1251-AGE albumin infusion strikingly decreased its deposition in the organs (Figs. 1 C Right and D Right, respectively), suggesting that AGE albumin is initially cleared from the circulation and deposited in the organs/ vasculature via a process which involves RAGE.
Ultrastructural Studies of AGE Albumin with the Vessel Wail. To assess vessel wall processing of infused AGEs, morphologic studies were performed with AGE albumin conjugated to colloidal gold particles, employing murine cardiac vasculature as a model system (23, 24) . Four minutes after in situ perfusion, AGE albumin-gold conjugates decorated numerous plasmalemmal vesicles opened to the luminal front ( Fig. 2A) , while coated pits and coated vesicles were unlabeled (Fig. 2B) . However, multivesicular bodies (Fig.  2B ) and structures resembling endosomes appeared significantly decorated by the tracer (Fig. 2 C and D) . Gold particles were also seen in the proximity of the abluminal endothelial cell surface (Fig. 2D) . Sparse gold particles were occasionally observed in the subendothelial space ( Fig. 2 A and D) , suggesting that transcytosis had occurred. At 15 min, the presence of AGE albumin-gold particles in the subendothelial space was even more apparent. These experiments were performed in the presence of a large excess of native albumin (3.5 mg/ml) to block the interaction of determinants on albumin with vessel wall albumin-binding proteins (24) (25) (26) (27) . In addition, the presence of excess free AGE albumin blocked association of AGE albumin-gold particles with the heart tissue by >50%o, while anti-RAGE IgG prevented such association by 50-70%6. Similar results were observed in studies using 125I-AGE albumin (data not shown).
Infusion ofAGE Albumin Leads to Induction ofIL-6 mRNA: Effect of Anti-RAGE IgG. AGEs have been reported to modulate cell properties in vitro, including the induction of genes for cytokines and growth factors (28, 29 association of diabetes with increased levels offibrinogen, an important risk factor for vascular complications (30) (31) (32) , the ability of infused AGE albumin to elevate mRNA levels of IL-6, a cytokine linked to fibrinogen synthesis (33) (34) (35) , was studied. Infusion of AGE albumin into normal mice led to an increase in IL-6 transcripts, compared with control animals infused with native albumin (Fig. 3A, lanes 3 and 2, respectively) . The migration of the PCR band amplified from AGE albumin-treated mice was identical to that induced by exposure of animals to bacterial lipopolysaccharide, a known inducer of IL-6 (33) (Fig. 3A, lane 6 ). Southern blotting of these PCR products with an oligonucleotide probe for murine IL-6 confirmed the identity of the above amplicons (Fig. 3B,  lanes 3 and 6, respectively) . The increase in IL-6 transcripts in response to AGE albumin was blocked by pretreatment of mice with anti-RAGE IgG, whereas nonimmune IgG was without effect (Fig. 3 A and B, lanes 4 and 5, respectively) . Heat treatment of these preparations abrogated their ability to induce IL-6 (data not shown). required to dissect the possible contribution of RAGE to vascular dysfunction, the current experiments establish that AGEs in the intravascular space recognize RAGE on the vessel wall as a major cell-associated target.
DISCUSSION

